Abstract 183P
Background
The incidence of gastric cancer is particularly high in Iran, where it remains a leading cause of cancer-related death, and it is the most common cancer among Iranian men, with an ASR of 21.6 per 100,000 men (GLOBO2018). By contrast the incidence and mortalityof gastric cancer rank fifth and third respectively worldwide. The aim of this study was to evaluate the epidemiologic profile of gastric cancer in East Azerbaijan, Iran.
Methods
In total, 2 years of cancer registry data were collected from different sources in East Azerbaijan (EA-PBCR), and a data quality check was performed to ensure clean data. Using the 2000 World Health Organization standard population, we then generated age-standardized incidence rates (ASRs) for different cancers, with data were generated for each year from 1394 to 1395 of the Persian calendar (i.e., 19 March 2015 to 20 March 2016).
Results
In total we registered 1700 gastric cancer in two years; 918 cases in 2015 and 712 cases in 2016. From these, 1181 cases were male and 519 cases were female, and the male to female ratio was 2.28. The mean age of the patients was 68.45 (±12.97) years, with age range of 21-99 years old. The most common age group was 7th decade with 531 (31.2%) gastric cancer cases. The most common morphological types were adenocarcinoma (n = 667, 39.2%), and intestinal type carcinoma (n = 421, 24.8%), and signet ring cell carcinoma (n = 119, 7%). The age standardized incidence rate (ASR) was 29.65 and 13.30 in males and females per 100,000, in 2015. The ASR was 26.48 and 9.91 in males and females per 100,000, in 2016. Gastric Cancer account for 12.4% of all cancers in both sexes, and the odds for men was 1.50, compared with women (OR 1.50; 95% CI = 1.33 – 1.71). After rigorous attempts, 63.5 % of the cases had microscopic verification (MV), and we collected 3.3 % of reports based on clinical data. The remaining data were collected from the cause of death registry or autopsy records, producing a final DCO% of 27.4%.
Conclusions
The ASR was decreased from 29.7 to 26.48 in men, and decreased from 13.3 to 9.91 in female. However gastric cancer is the most common cancer in terms of incidence and mortality in East Azerbaijan, according to last results of EA-PBCR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract